A phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf حسب Chalmers, James D., Gupta, Abhya, Chotirmall, Sanjay Haresh, Armstrong, April, Eickholz, Peter, Hasegawa, Naoki, McShane, Pamela J., O'Donnell, Anne E., Shteinberg, Michal, Watz, Henrik, Eleftheraki, Anastasia, Diefenbach, Claudia, Sauter, Wiebke

احصل على النص الكامل